Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Experimental PfSPZ Vaccine in Adults Without Malaria

ABSTRACT: Experimental PfSPZ Vaccine in Adults Without Malaria

PROVIDER: PRJNA729130 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Experimental PfSPZ Vaccine in Adults Without Malaria

Project description:Experimental PfSPZ Vaccine in Adults Without Malaria

| PRJNA729131 | ENA

Transcription profiling of PfSPZ Malaria Vaccine trial subjects in a malaria endemic region

Project description:The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. The PfSPZ Vaccine trial in Mali was the first to evaluate the safety and efficacy of this vaccine in a malaria endemic region. Vaccinees received five doses of 2.7 X 105 irradiated sporozoites and the efficacy was measured against naturally occurring Pf Infections in Malian adults during the malaria transmission season.

2017-01-01 | GSE86308 | GEO

Transcription profiling of PfSPZ Malaria Vaccine trial subjects receiving a 3-dose regimen in a malaria endemic region

Project description:The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. Vaccinees received 3 doses of 1.8 X 106 irradiated sporozoites. Efficacy was measured by challenged by controlled human malaria infections (CHMI), and against naturally occurring Pf Infections in Malian adults during the malaria transmission season

2022-08-20 | GSE211599 | GEO

Transcription profiling of PfSPZ Vaccine trial subjects (US, malaria naïve) receiving a 3-dose or 5-dose regimen

Project description:The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. Vaccinees received either 3 doses of 1.8M irradiated sporozoites or 5 doses of 270K. Efficacy was measured by challenged by controlled human malaria infections (CHMI) at 3 weeks and 24 weeks after the last vaccine dose

2022-08-22 | GSE211626 | GEO

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

Project description:Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

| PRJNA729132 | ENA

Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

Project description:Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults

| PRJNA729133 | ENA

Transcription profiling of PfSPZ Malaria Vaccine trial subjects receiving a 3-dose regimen in a malaria endemic region

Project description:Transcription profiling of PfSPZ Malaria Vaccine trial subjects receiving a 3-dose regimen in a malaria endemic region

| PRJNA871032 | ENA

Gene expression profiling after vaccination with the RTS,S candidate malaria vaccine in a controlled human malaria infection study

Project description:RTS,S is the sole candidate vaccine shown to provide protection against infection to malaria-naive adults challenged with mosquito-borne homologous falciparum malaria and protection against infection and clinical and severe disease to volunteers in malaria-endemic Africa who were exposed to diverse Plasmodium falciparum strains. In this experiment we profiled gene expression in PBMCs after vaccination with the RTS,S candidate malaria vaccine in a controlled human malaria infection study. Subjects were vaccinated with three doses of the RTS,S candidate malaria vaccine. Blood samples for PBMC isolation and subsequent gene expression analysis were taken on day 0 (0m), day of the third vaccination (8w), 1 day post third vaccination (8w1d), 3 days post third vaccination (8w3d), the day of the infection (10w), 1 day post infection (10w1d), and 5 days post infection (10w5d). After infection the subjects were closely monitored for parasitemia. The response to the controlled infection was recorded as follows: no parasitemia (P, protected), parasitemia in the same time frame as the control group (NP, not protected), parasitemia later than the control group (DL, delayed). In addition to the experimental factors, a confounding factor was identified in the data analysis related to the use of a specific kit batch (Kit A or B).

2017-04-27 | E-MTAB-4629 | biostudies-arrayexpress

Expression data from whole blood samples of Rwandan adults with mild malaria with matched sample thirty days later (convalescence)

Project description:Host factors governing mild disease in adults who have developed clinical immunity to Plasmodium falciparum may provide insights for disease altering vaccine or interventions, to prevent severe malaria We used microarrays of whole blood samples during mild malaria and compared them in a paired analysis to whole blood microarray 30 days later. (n=19 pairs)

2014-12-19 | GSE64338 | GEO

Transcription profiling of PfSPZ Vaccine trial subjects (US, malaria naïve) receiving a 3-dose or 5-dose regimen

Project description:Transcription profiling of PfSPZ Vaccine trial subjects (US, malaria naïve) receiving a 3-dose or 5-dose regimen

| PRJNA871225 | ENA